Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of October 29, 2026, BCAX trades at $9.55 with a market cap of $1.16B and a P/E ratio of -6.53. BCAX moved -44.39% today. Year to date, BCAX is -40.42%; over the trailing twelve months it is -42.89%. Its 52-week range spans $7.80 to $30.99. Analyst consensus is strong buy with an average price target of $33.33. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
9 analysts cover BCAX: 0 strong buy, 7 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $33.33.
| Metric | Value |
|---|---|
| Price | $9.55 |
| Market Cap | $1.16B |
| P/E Ratio | -6.53 |
| EPS | $-2.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.99 |
| 52-Week Low | $7.80 |
| Volume | 14.75M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.95M |
| Gross Margin | 0.00% |
9 analysts cover BCAX: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.33.